Breaking News

Rigenerand Announces Orphan Drug Designations from both EMA and FDA Obtained by RR001 for the Treatment of Pancreatic Cancer

Rigenerand srl announces the positive opinion on orphan drug designation (ODD) issued by the European Medicines Agency (EMA) for RR001, for the treatment of pancreatic cancer. This relevant milestone immediately follows the ODD granted by the FDA (USA) on May 2018 for the same indication.

Rigenerand is presenting VITVO at the AACR meeting in Chicago on April, 14/18 2018

Visit us at booth 4207 and explore the VITVO® infinite possibilities of culturing in the 3D dimension.

Rigenerand brings novelty at the 3D Tissue Models Oncology Congress in Boston on May, 8/10 2018

Rigenerand shares data on its novel 3D culture system during the 3D Tissue Models Oncology Congress in Boston.